Logo image of PROK

PROKIDNEY CORP (PROK) Stock Price, Quote, News and Overview

NASDAQ:PROK - Nasdaq - KYG7S53R1049 - Common Stock - Currency: USD

0.6372  +0.06 (+10.11%)

After market: 0.7 +0.06 (+9.86%)

PROK Quote, Performance and Key Statistics

PROKIDNEY CORP

NASDAQ:PROK (7/3/2025, 8:01:30 PM)

After market: 0.7 +0.06 (+9.86%)

0.6372

+0.06 (+10.11%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.59
52 Week Low0.46
Market Cap186.51M
Shares292.70M
Float90.50M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-30 2021-06-30


PROK short term performance overview.The bars show the price performance of PROK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

PROK long term performance overview.The bars show the price performance of PROK in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PROK is 0.6372 USD. In the past month the price decreased by -19.24%. In the past year, price decreased by -71.68%.

PROKIDNEY CORP / PROK Daily stock chart

PROK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.34B
AMGN AMGEN INC 14.37 160.37B
GILD GILEAD SCIENCES INC 14.44 139.01B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.03B
REGN REGENERON PHARMACEUTICALS 12.35 59.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.28B
ARGX ARGENX SE - ADR 94.52 33.18B
ONC BEONE MEDICINES LTD-ADR 6.27 26.57B
BNTX BIONTECH SE-ADR N/A 26.44B
NTRA NATERA INC N/A 22.09B
BIIB BIOGEN INC 8.4 19.47B
SMMT SUMMIT THERAPEUTICS INC N/A 18.23B

About PROK

Company Profile

PROK logo image ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.

Company Info

PROKIDNEY CORP

2000 Frontis Plaza Blvd., Suite 250

Winston-Salem NORTH CAROLINA US

Employees: 163

PROK Company Website

PROK Investor Relations

Phone: 13369997028

PROKIDNEY CORP / PROK FAQ

What is the stock price of PROKIDNEY CORP today?

The current stock price of PROK is 0.6372 USD. The price increased by 10.11% in the last trading session.


What is the ticker symbol for PROKIDNEY CORP stock?

The exchange symbol of PROKIDNEY CORP is PROK and it is listed on the Nasdaq exchange.


On which exchange is PROK stock listed?

PROK stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PROKIDNEY CORP stock?

12 analysts have analysed PROK and the average price target is 4.59 USD. This implies a price increase of 620.34% is expected in the next year compared to the current price of 0.6372. Check the PROKIDNEY CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PROKIDNEY CORP worth?

PROKIDNEY CORP (PROK) has a market capitalization of 186.51M USD. This makes PROK a Micro Cap stock.


How many employees does PROKIDNEY CORP have?

PROKIDNEY CORP (PROK) currently has 163 employees.


What are the support and resistance levels for PROKIDNEY CORP (PROK) stock?

PROKIDNEY CORP (PROK) has a support level at 0.56 and a resistance level at 0.75. Check the full technical report for a detailed analysis of PROK support and resistance levels.


Should I buy PROKIDNEY CORP (PROK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROKIDNEY CORP (PROK) stock pay dividends?

PROK does not pay a dividend.


What is the Price/Earnings (PE) ratio of PROKIDNEY CORP (PROK)?

PROKIDNEY CORP (PROK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.6).


What is the Short Interest ratio of PROKIDNEY CORP (PROK) stock?

The outstanding short interest for PROKIDNEY CORP (PROK) is 18.56% of its float. Check the ownership tab for more information on the PROK short interest.


PROK Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PROK Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PROK. While PROK seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PROK Financial Highlights

Over the last trailing twelve months PROK reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -5.26% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -16.85%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%18.75%
Sales Q2Q%N/A
EPS 1Y (TTM)-5.26%
Revenue 1Y (TTM)N/A

PROK Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to PROK. The Buy consensus is the average rating of analysts ratings from 12 analysts.


Ownership
Inst Owners41.87%
Ins Owners4.39%
Short Float %18.56%
Short Ratio15.66
Analysts
Analysts78.33
Price Target4.59 (620.34%)
EPS Next Y9.37%
Revenue Next YearN/A